~~<i id='E7E1DB729D'><strike id='E7E1DB729D'><tt id='E7E1DB729D'><pre id='E7E1DB729D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：comprehensive 2025-10-01 10:58:30 - browse：3618

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Medicare inequities exacerbate Puerto Rico’s health disparities

hotspot

entertainment

focus

leisure time

explore

Wikipedia

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

WSS

Black vets could get higher VA benefits if race not used in lung test

Alabama frozen embryo ruling has major implications for IVF clinics

He's a Nobel laureate. Critics say he was misleading on Covid

HHS's proposed rule does nothing to address the climate crisis

STAT readers on older presidents, polypills, Medicare, and more

R1 RCM gets $5.8 billion buyout offer from private equity firm

focus

focus

hotspot

Hollywood unions extend contract negotiations for actors

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Virginia high school admissions case could be legal follow

BIO to announce reorganization, senior leaders expected to depart

The high cost of giving birth even with insurance

Class action alleges UnitedHealth concealed DOJ probe

The high cost of giving birth even with insurance

Deliver public health messages at the right time

Duchenne breakthrough therapy leaves behind pioneering families

Novel spinal cord stimulator treats paralysis without surgery

entertainment

In utero gene editing: an explainer

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

HHS's proposed rule does nothing to address the climate crisis

Antivenom research: Lessons from HIV applied in search for universal antidote

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Warren pushes Witty on UnitedHealth's control over physicians

focus

leisure time

explore

Wikipedia